AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Image Source: Unsplash
An Introduction
According to research from Grand View Research, the AI-powered drug discovery process is expected to grow by a compound annual growth rate of 30% between now and 2030 and, according to Morgan Stanley, should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The AI-focused Drug Discovery Stocks Portfolio
The 6 AI-focused clinical-stage drug discovery stocks currently trading on Canadian or American stock exchanges are tracked in our AI-focused Drug Discovery Stocks Portfolio are highlighted below, in descending order, for last week (e/e September 6th) and in August, along with a description of their areas of focus, their market capitalizations, their product pipeline and the latest news, analyses and commentary on each, where pertinent:
- Schrödinger (SDGR): DOWN 2.5% w/e Sept. 6th; DOWN 5.6% in August
- Area of Focus: uses its platform to discover novel molecules which it leverages to build a pipeline of its own clinical programs in addition to selling access to its platform to other pharmaceutical firms (see details here)
- Market Capitalization: $1,490M
- Pipeline: (see here)
- Latest News, Analyses and Commentary:
- AbCellera Biologics (ABCL): DOWN 6.6% w/e Sept. 6th; DOWN 21.5% in August
- Relay Therapeutics (RLAY): DOWN 8.1% w/e Sept. 6th; DOWN 17.4% in August
- Absci Corporation (ABSI): DOWN 8.6% w/e Sept. 6th; No Change in August
- Exscientia (EXAI): DOWN 11.9% w/e Sept. 6th; UP 5.1% in August
- Recursion Pharmaceuticals (RXRX): DOWN 18.7% w/e Sept. 6th; DOWN 11.2% in August
Summary
On average, the 6 constituents in our AI-focused Drug Discovery Stocks Portfolio (averaging $963M in market capitalization) went DOWN 7.7% w/e Sept.6th, as compared to -0.8% the previous week and went DOWN 7.8% in August vs. going UP 16.1% during July.
More By This Author:
Our 6-Part Computer Chips Portfolio Was Down 2% In August
These AI-Related Stocks Were Down +10% Week Ending September 6
Our Micro/Small Cap AI Stocks Portfolio Went Down 5% In August
Disclosure: None
This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...
moreComments
![](/images/tinyMceCommentImg.png)